BridgeBio’s Attruby sales expand as a one-time milestone boosts quarterly revenue

BridgeBio ($BBIO) reported third-quarter 2026 revenue of $353.2 million, compared with $120.7 million a year earlier. US Attruby sales reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year. License and services revenue included a one-time $75 million payment triggered by partner Bayer ($BAYN)’s Beyonttra sales, while royalty revenue reached $20.5 million.

The operating loss narrowed to $11.6 million, although the loss attributable to common shareholders remained $83.0 million after financing charges, preferred dividends and other items. Cash and investments totaled approximately $1.5 billion. Management said that balance funds three planned launches and expansion programs, but future launches still depend on regulatory approvals. The quarter demonstrates stronger commercial demand while the milestone payment limits how much of the revenue increase can be treated as recurring product growth.

Sources:

• GlobeNewswire